Department of Obstetrics and Gynecology, Baskent University, Ankara, Turkey.
Arch Gynecol Obstet. 2011 Nov;284(5):1081-5. doi: 10.1007/s00404-010-1797-2. Epub 2010 Dec 8.
Our aim in this study was to investigate the association between 1-h glucose challenge test (GCT) of 130-140 mg/dl and the development of macrosomia.
In this retrospective cohort study, patients with GCT between 130 and 140 mg/dl were divided into two groups. Macrosomic and appropriate-for-gestational-age (AGA) term neonates were compared for the presence of maternal risk factors and fetal abdominal circumference between 29 and 34 weeks.
There were no significant differences between the groups with respect to maternal age, parity, BMI at the first trimester and at the time of GCT, gestational weeks at delivery. However; history of a macrosomic baby delivery was significantly higher in macrosomic group (33.3% for group 1, 11.3% for group 2, p = 0.001). Abdominal circumference at 29-34 weeks of gestations was significantly higher in macrosomic group (32.46 ± 1.97 for group 1 vs. 31.06 ± 2.46 for group 2, p = 0.002).
History of a macrosomic baby delivery and abdominal measurement at 29-34 weeks was important predictors of macrosomia in patients with GCT between 130 and 140 mg/dl.
本研究旨在探讨 130-140mg/dl 1 小时葡萄糖挑战试验(GCT)与巨大儿发生之间的关系。
在这项回顾性队列研究中,将 GCT 在 130-140mg/dl 之间的患者分为两组。比较巨大儿和适当胎龄(AGA)足月新生儿的母亲危险因素和 29-34 周时胎儿腹围。
两组间母亲年龄、产次、孕早期和 GCT 时 BMI、分娩时孕周均无显著差异;但巨大儿组巨大儿分娩史明显较高(1 组 33.3%,2 组 11.3%,p=0.001)。29-34 周时的腹围在巨大儿组中明显更高(1 组 32.46±1.97 比 2 组 31.06±2.46,p=0.002)。
巨大儿分娩史和 29-34 周时的腹部测量是 GCT 在 130-140mg/dl 之间的患者发生巨大儿的重要预测指标。